MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA ...

FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to ...

Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, ...

The drug is now expected to be available in the U.S. in the second half of January 2026. ・The prescribing information for the ...

The FDA has approved aficamten (Myqorzo; Cytokinetics), a cardiac myosin inhibitor, for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). 1 ...

Researchers identified distinct demographic, clinical, and serologic predictors of incident LVSD and cardiac recovery among patients with SSc.

Are you ready to heal the failing heart and rescue its beat? PERM1, a promising protein, paves the way for new treatments for systolic heart failure. The heart, an extraordinary muscle, beats ...

Heart failure sounds alarming—and rightfully so. Yet approximately 6.5 million Americans currently live with this condition, many with the specific variant called systolic heart failure, and a ...

It is a common perception that approximately 50% of heart failure (HF) patients present with a normal or near-normal left ventricular (LV) ejection fraction ("HF with preserved systolic function"), ...

Through a deep-learning model, researchers have shown that ordinary ECG images can be leveraged to identify patients with an LV ejection fraction below 40%. Their approach also appears able to ...

You have a 76-year-old patient with heart failure that was diagnosed 2 months ago. She has a history of hypertension, which is being treated with amlodipine. On her initial visit 2 months previously, ...

The US Food and Drug Administration has approved aficamten (Myqorzo), an allosteric cardiac myosin inhibitor, for adults with ...